REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $35.64.

A number of brokerages have recently issued reports on RGNX. Morgan Stanley restated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Tuesday, October 22nd. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. HC Wainwright lifted their target price on REGENXBIO from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th.

Insider Activity

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the transaction, the director now owns 11,286 shares in the company, valued at approximately $130,466.16. This represents a 46.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 13.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds have recently bought and sold shares of RGNX. Redmile Group LLC grew its position in shares of REGENXBIO by 21.0% in the first quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock valued at $95,901,000 after purchasing an additional 790,866 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 258.7% in the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock worth $9,552,000 after acquiring an additional 588,773 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of REGENXBIO by 9.8% in the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock valued at $102,756,000 after purchasing an additional 436,043 shares in the last quarter. Artal Group S.A. bought a new position in REGENXBIO in the first quarter worth $5,268,000. Finally, Integral Health Asset Management LLC raised its stake in REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after acquiring an additional 190,000 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Performance

RGNX opened at $9.63 on Friday. REGENXBIO has a fifty-two week low of $8.53 and a fifty-two week high of $28.80. The company has a fifty day moving average of $10.50 and a two-hundred day moving average of $12.28. The stock has a market capitalization of $477.07 million, a price-to-earnings ratio of -1.91 and a beta of 1.23.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.